利湿活血通络方联合阿达木单抗治疗湿热瘀阻型类风湿性关节炎临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R684

基金项目:

海宁市科技计划项目(2018075)


Clinical Study on Lishi Huoxue Tongluo Prescription Combined with Adamumab for Rheumatoid Arthritis of Damp-Heat Stasis Obstruction Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察利湿活血通络方联合阿达木单抗治疗湿热瘀阻型类风湿性关节炎的临床疗效。方法: 采用随机数字表法将 124 例湿热瘀阻型类风湿性关节炎分为对照组、观察组各 62 例。对照组予阿达木单抗治 疗,观察组在对照组基础上联用利湿活血通络方治疗。比较 2 组治疗前后中医证候积分、炎症指标、血液流变 学指标、临床疾病活动指数(CDAI)、视觉模拟评分法(VAS)评分、Lysholm 膝关节量表评分,评估 2 组临 床疗效及不良反应发生情况。结果:观察组总有效率 91.94%,高于对照组 77.42%(P<0.05)。2 组治疗后中 医证候积分、CDAI、VAS 评分均较治疗前降低(P<0.05),Lysholm 膝关节量表评分升高(P<0.05);观察组 治疗后中医证候积分、CDAI、VAS 评分低于对照组 (P<0.05),Lysholm 膝关节量表评分高于对照组(P< 0.05)。2 组治疗后抗环瓜氨酸肽 (CCP)、人附睾蛋白 4 (HE4)、Nod 样受体蛋白 3 (NLRP3)、全血黏 度(WBV)、D-二聚体(D-D)、纤维蛋白原(FIB)、红细胞聚集指数(EAI)均低于治疗前(P<0.05),观察 组治疗后上述炎症指标与血液流变学指标均低于对照组(P<0.05)。2 组不良反应发生率比较,差异无统计学 意义(P>0.05)。结论:利湿活血通络方联合阿达木单抗治疗湿热瘀阻性类风湿性关节炎疗效确切,能降低患 者炎症因子水平,改善血液流变学指标,安全性较高。

    Abstract:

    Abstract:Objective:To observe the clinical effect of the therapy of Lishi Huoxue Tongluo Prescription combined with Adamumab on rheumatoid arthritis of damp-heat stasis obstruction type. Methods:A total of 124 cases with rheumatoid arthritis of damp-heat stasis obstruction type were divided into the control group and the observation group according to random number table method,with 62 cases in each group. The control group was treated with Adamumab,and the observation group was additionally treated with Lishi Huoxue Tongluo Prescription based on the treatment of the control group. The traditional Chinese medicine (TCM) syndrome scores,inflammation indexes,hemorheology indexes,Clinical Disease Activity Index (CDAI),Visual Analogue Scale (VAS),Lysholm knee scale score were compared before and after treatment between the two groups. The clinical effect and the occurrence of adverse reactions were evaluated in both groups. Results:The total effective rate was 91.94% in the observation group,higher than that of 77.42% in the control group (P<0.05). After treatment,the TCM syndrome scores and the scores of CDAI and VAS in the two groups were decreased when compared with those before treatment (P<0.05),and the Lysholm knee scale scores were increased (P<0.05);the TCM syndrome score and scores of CDAI and VAS in the observation group were lower than those in the control group (P<0.05),and the Lysholm knee scale score was increased (P<0.05). After treatment,the cyclic citrullinated peptide (CCP),human epididymal protein 4 (HE4),Nod-like receptor protein 3 (NLRP3),whole blood viscosity (WBV),D-dimer (D-D),fibrinogen (FIB) and Erythrocyte Aggregation Index (EAI) in the two groups were all decreased when compared with those before treatment (P<0.05),and the inflammation indexes and hemorheology indexes in the observation group were lower than those in the control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:The therapy of Lishi Huoxue Tongluo Prescription combined with Adamumab has a definite clinical effect on the treatment of rheumatoid arthritis of damp-heat stasis obstruction type,which can reduce the levels of inflammatory factors and improve hemorheology indexes in patients,with great safety.

    参考文献
    相似文献
    引证文献
引用本文

李玉,戚徐斌,朱亚琴.利湿活血通络方联合阿达木单抗治疗湿热瘀阻型类风湿性关节炎临床研究[J].新中医,2023,55(15):90-94

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-08-13
  • 出版日期:
文章二维码